A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages by Turnbull, Catriona M. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha
release from LPS-activated human monocytes and macrophages
Citation for published version:
Turnbull, CM, Marcarino, P, Sheldrake, TA, Lazzarato, L, Cena, C, Fruttero, R, Gasco, A, Fox, S, Megson,
IL & Rossi, AG 2008, 'A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha release from LPS-
activated human monocytes and macrophages' Journal of inflammation, vol 5, 12, pp. -. DOI: 10.1186/1476-
9255-5-12
Digital Object Identifier (DOI):
10.1186/1476-9255-5-12
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Journal of inflammation
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 28. Apr. 2017
BioMed Central
Page 1 of 10
(page number not for citation purposes)
Journal of Inflammation
Open AccessResearch
A novel hybrid aspirin-NO-releasing compound inhibits TNFalpha 
release from LPS-activated human monocytes and macrophages
Catriona M Turnbull1, Paolo Marcarino2, Tara A Sheldrake4, 
Loretta Lazzarato2, Clara Cena2, Roberta Fruttero2, Alberto Gasco2, 
Sarah Fox4, Ian L Megson3 and Adriano G Rossi*4
Address: 1Centre for Cardiovascular Science Queen's Medical Research Institute, University of Edinburgh, Edinburgh, EH16 4TJ, UK, 
2Dipartimento di Scienza e Tecnologia del Farmaco, Università degli Studi di Torino, Turin, Italy, 3Free Radical Research Facility, UHI Millennium 
Institute, Inverness, IV2 3BL, UK and 4MRC Centre for Inflammation Research, Queen's Medical Research Institute, University of Edinburgh, 
Edinburgh, EH16 4TJ, UK
Email: Catriona M Turnbull - catriona.scott@ed.ac.uk; Paolo Marcarino - paolo.marcarino@unito.it; 
Tara A Sheldrake - Tara.Sheldrake@ed.ac.uk; Loretta Lazzarato - loretta.lazzarato@unito.it; Clara Cena - clara.cena@unito.it; 
Roberta Fruttero - roberta.fruttero@unito.it; Alberto Gasco - alberto.gasco@unito.it; Sarah Fox - sfox1@staffmail.ed.ac.uk; 
Ian L Megson - ian.megson@uhi.ac.uk; Adriano G Rossi* - a.g.rossi@ed.ac.uk
* Corresponding author    
Abstract
Background: The cytoprotective nature of nitric oxide (NO) led to development of NO-aspirins
in the hope of overcoming the gastric side-effects of aspirin. However, the NO moiety gives these
hybrids potential for actions further to their aspirin-mediated anti-platelet and anti-inflammatory
effects. Having previously shown that novel NO-aspirin hybrids containing a furoxan NO-releasing
group have potent anti-platelet effects, here we investigate their anti-inflammatory properties.
Here we examine their effects upon TNFα release from lipopolysaccharide (LPS)-stimulated human
monocytes and monocyte-derived macrophages and investigate a potential mechanism of action
through effects on LPS-stimulated nuclear factor-kappa B (NF-κB) activation.
Methods: Peripheral venous blood was drawn from the antecubital fossa of human volunteers.
Mononuclear cells were isolated and cultured. The resultant differentiated macrophages were
treated with pharmacologically relevant concentrations of either a furoxan-aspirin (B8, B7; 10 μM),
their respective furazan NO-free counterparts (B16, B15; 10 μM), aspirin (10 μM), existing
nitroaspirin (NCX4016; 10 μM), an NO donor (DEA/NO; 10 μM) or dexamethasone (1 μM), in
the presence and absence of LPS (10 ng/ml; 4 h). Parallel experiments were conducted on
undifferentiated fresh monocytes. Supernatants were assessed by specific ELISA for TNFα release
and by lactate dehydrogenase (LDH) assay for cell necrosis. To assess NF-κB activation, the effects
of the compounds on the loss of cytoplasmic inhibitor of NF-κB, IκBα (assessed by western
blotting) and nuclear localisation (assessed by immunofluorescence) of the p65 subunit of NF-κB
were determined.
Results: B8 significantly reduced TNFα release from LPS-treated macrophages to 36 ± 10% of the
LPS control. B8 and B16 significantly inhibited monocyte TNFα release to 28 ± 5, and 49 ± 9% of
control, respectively. The B8 effect was equivalent in magnitude to that of dexamethasone, but was
not shared by 10 μM DEA/NO, B7, the furazans, aspirin or NCX4016. LDH assessment revealed
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none of the treatments caused significant cell lysis. LPS stimulated loss of cytoplasmic IκBα and
nuclear translocation of the p65 NF-κB subunit was inhibited by the active NO-furoxans.
Conclusion: Here we show that furoxan-aspirin, B8, significantly reduces TNFα release from both
monocytes and macrophages and suggest that inhibition of NF-κB activation is a likely mechanism
for the effect. This anti-inflammatory action highlights a further therapeutic potential of drugs of
this class.
Background
Aspirin (acetylsalicylic acid) was first synthesized in 1899
and was the first example of the family of nonsteroidal
anti-inflammatory drugs (NSAIDs). Its therapeutic uses
include the treatment of headache, rheumatic pain and
inflammation, in addition to being utilised as an effective
prophylactic against thrombotic events in the cardiovas-
cular system. The anti-inflammatory effects of aspirin are
achieved primarily through inhibition of cyclooxygenase-
mediated synthesis of pro-inflammatory prostanoids [1];
it causes irreversible inhibition by selectively and rapidly
acetylating a serine residue (Ser 530) near the C-terminus
of the cyclooxygenase (COX) family of enzymes, forming
an impediment to the binding of arachidonic acid [2-4].
The acetylation evokes a requirement for new COX to be
synthesised for subsequent production of prostaglandins.
Unfortunately, gastrointestinal disorders, including ulcer-
ation, are a common side-effect of aspirin, limiting its
long-term use [5-8]. The effect is primarily believed to be
due to inhibition of the production of prostaglandins that
normally protect the gastric mucosa [8-11].
Aspirin esters containing a nitric oxide (NO)-donor moi-
ety overcome the gastric side-effects [12,13] likely via the
cytoprotective effects of drug-derived NO. NO increases
blood flow in the gastric mucosa, promoting repair and
removal of toxins [14]. NO also increases secretion of pro-
tective gastric mucus [15] and is thought to promote heal-
ing of gastric ulcers by promoting angiogenesis [16].
Alternatively, or in addition, the protective effects of NO-
aspirin could be due to masking of the carboxylic acid
moiety by the ester function [12,17]. Two main subtypes
of NO-aspirins have so far been developed: the nitrooxy
ester (organic nitrate) derivatives and the furoxan deriva-
tives. The first NO-aspirin hybrid drugs to be synthesised,
the NicOx® compounds, NCX4016 (3-(nitroxyme-
thyl)phenyl 2-(acetoxy)benzoate; Fig. 1a) and the related,
NCX4215 [18] are both nitrooxy ester derivatives of aspi-
rin, often referred to as "nitroaspirins". More recently,
another series of NO-aspirin hybrid drugs, the furoxan
derivatives, which utilise a furoxan NO-donor moiety
have been developed [12,19]. These drugs link an NO-
donating moiety (furoxan group) by ester linkage to the
aspirin molecule (Fig. 1b). Furoxan hybrids of aspirin
with NO donor moieties have shown some benefit in
avoiding acute gastric injury [12], and to be effective
antiplatelet agents [19]. As the compounds have been
demonstrated to inhibit COX, they have the potential to
retain an aspirin-like anti-inflammatory action. Through
their NO release [19], these drugs gain further potential to
be anti-inflammatory through the multiple actions of NO
[for review see; [20]].
This manuscript explores the impact of two of these novel
hybrid compounds and of the furazan analogues, devoid
of NO-release capacity (Fig. 1c), on release of the pro-
Structural formulaeFig re 1
Structural formulae: a. The structural formula of NO-
aspirin, NCX4016.  b. The general structural formula of a 
furoxan-aspirin hybrid drug. c. The structural formulae of 
furoxans (B8 and B7), their NO-free equivalents, the furazans 
(B16 and B15) and, for comparison, aspirin.
a 
b 
c 
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inflammatory cytokine, TNFα from human monocyte-
derived macrophages and monocytes. Cytokines are
polypeptide or glycoprotein factors that act in an auto-
crine and/or paracrine fashion to signal in a variety of bio-
logical processes. They are generally considered to be
either pro-inflammatory (e.g. TNFα and interleukin (IL)-
8) or anti-inflammatory [e.g. TGFβ and IL-10] although
they can have paradoxical actions. Cytokines act in vari-
ous cell types and perform diverse functions. TNFα is
secreted by monocytes, macrophages and neutrophils fol-
lowing their stimulation by bacterial LPS. The various
activities of TNFα include mediation of cell adhesion
molecules [21], regulation of cell death in tumour cells
[22], enhancement of neutrophil responsiveness [23],
control of neutrophil adherence to the endothelium [21]
and synthesis of IL-1 production by macrophages [24].
LPS is known to stimulate TNFα production via the acti-
vation of the transcription factor, NF-κB [25-27]. It is well
known that anti-inflammatory glucocorticoids such as
dexamethasone can inhibit release of cytokines such as
TNFα from cells stimulated with LPS [28-30]. Possible
mechanisms include the ability of glucocorticoids to effec-
tively suppress pro-inflammatory transcription factors
such as NF-κB [31] through stimulation of glucocorticoid
receptors, which subsequently translocate to the nucleus
preventing histone acetylation, a vital step in the NF-κB-
induced gene transcription [31,32]. Other mechanisms by
which the glucocorticoid receptor reduces TNFα expres-
sion include decreasing mRNA stability, inducing expres-
sion of the inhibitor IκB, and altering co-factor (AP-1)
activity [33]. NO and aspirin have both been previously
shown to influence the release of TNFα likely through
modulation of NF-κB function [34-42], thus hybrid NO-
aspirins may have increased anti-inflammatory potential
through the dual action of NO and aspirin moieties on
this pathway. Here, we set out to determine if novel NO-
releasing furoxan derivatives of aspirin possess anti-
inflammatory properties in LPS-activated human mono-
cyte-derived macrophages and monocytes through analy-
sis of TNFα release and the NF-κB pathway. The relative
contribution of the aspirin and NO moieties on these
effects were also addressed through the use of NO-free
furazan counterpart drugs, the NO donor, DEA/NO and
aspirin compounds.
Methods
Materials
General laboratory supplies were purchased from Sigma
(Poole, UK) unless otherwise stated. 2-(N,N-
diethyamino)-diazenolate-2-oxide (DEA/NO; Axxora,
Nottingham, U.K.) was dissolved and stored frozen in
0.01 M NaOH prior to final dilution with phosphate-buff-
ered saline (PBS) immediately prior to use. All NO-aspirin
hybrids were synthesized at the Università degli Studi di
Torino, as described [12]. They were dissolved in dimethyl
sulfoxide (DMSO) then diluted in PBS to give a final
DMSO concentration ≤ 0.1%.
Preparation of Monocytes and Macrophages
Peripheral venous blood was drawn from the antecubital
fossa of human volunteers (non-smokers; age 20–45
years). Mononuclear cells were isolated by dextran sedi-
mentation and discontinuous Percoll gradient centrifuga-
tion as described [43]. Mononuclear cells were
resuspended at a concentration of 4 × 106 cells/ml in
Iscove's DMEM. Monocytes were plated out in 48-well
plates at a concentration of 2 × 106 per well or 6-well
plates at 12 × 106 per well. After 1 h, non-adherent cells
were removed by washing wells with Hank's buffered salt
solution (HBSS). Macrophages were derived from mono-
cytes by culturing the monocytes in Iscove's DMEM (sup-
plemented with 10% autologous serum) at 37°C for a
week, with the medium being changed after 3–4 days
[44].
Stimulation of Cells
For macrophages, on day 7, the medium in each well was
changed and fresh medium containing 10 μM test drug or
a DMSO vehicle control added to wells with or without
the inflammatory stimulant, LPS (10 ng/ml). Drug con-
centrations were selected based on results from pilot stud-
ies and on realistic plasma concentrations, where these
data are available; 10 μM was deemed a relevant plasma
level for aspirin, and so was utilised in this study. In order
to facilitate direct comparisons, the effects of the hybrid
compounds were also investigated at 10 μM. Drugs inves-
tigated were the furoxan-aspirin hybrids (3-cyanofuroxan-
4-yl)methyl 2-acetoxybenzoate (B8) and (3-carbamoyl-
furoxan-4-yl)methyl 2-acetoxybenzoate (B7), their
respective NO-free counterparts (furazans), (4-cyanofura-
zan-3-yl)methyl 2-(acetoxy)benzoate (B16) and (4-car-
bamoylfurazan-3-yl)methyl 2-acetoxybenzoate (B15),
nitroaspirin NCX4016, NO donor, DEA/NO or dexame-
thasone (1 μM). Cells were then incubated at 37°C for 4
h before removal of the cell supernatants, which were sub-
sequently frozen at -70°C for future studies. The same
procedure was also carried out on monocytes that had not
been matured into macrophages with drug treatments and
4 h incubations taking place immediately after the final
cell washing step of the isolation procedure.
Enzyme-Linked Immunosorbent Assay (ELISA)
A human TNFα ELISA kit was purchased from BD Bio-
sciences (cat no; 550610) and performed as per kit
instructions on the supernatants removed from macro-
phage or monocyte cultures. The absorbance of each well
was read at 450 nm using a Thermo Labsystems Multiskan
Ascent plate reader running Ascent software Version 2.6.
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Lactate Dehydrogenase (LDH) Assay
The cytotoxic impact of the compounds was assessed by
measuring release of the enzyme LDH in the supernatant
using a kit purchased from Roche (cat no. 1 644 793).
Western blotting for IκBα
Using 6-well plates, mononuclear cells were prepared as
above. Following washing, cells were treated with Iscove's
DMEM supplemented with 10% autologous serum con-
taining either B8 (1 μM, 10 μM, 20 μM, 100 μM), glio-
toxin (0.1 μg/ml), buffer or a DMSO vehicle control
(0.2%) for 30 min at 37°C. LPS (10 ng/ml) or medium
was then added to appropriate wells and left to incubate
for a further 45 min as described for the immunofluores-
cence experiment (see below). Lysates were prepared at
4°C using a protease inhibitor cocktail in TBS with 1%
Nonidet P40 in order to minimise proteolysis problems.
An aliquot of each lysate was used for total protein deter-
mination using a BCA protein assay kit (Pierce, Rockford,
IL) and an equivalent of 24 μg of protein per well was run
on a 12% SDS-PAGE gel and transferred to PVDF. Blots
were blocked with 5% skimmed milk in TBS/0.1% Tween-
20 before probing with rabbit IκB-α (AbCam, cat no.
32518-100) [45] diluted 1:2500, incubated overnight at
4°C. Subsequently, the blots were washed and incubated
with goat anti-rabbit HRP (DakoCytomation, cat no.
P0448), also diluted 1:2500, and developed using stand-
ard ECL (GE Healthcare).
Immunofluorescence for NF-κB p65 Subunit
Immunofluorescence for the p65 subunit was used to vis-
ualise the translocation of NF-κB. Mononuclear cells were
isolated and resuspended as described above. 4 × 106 (1
ml) cells were placed on a glass coverslip within a 6-well
plate and left in an incubator (37°C; 1 h) to adhere. Non-
adherent cells were then removed by washing wells with
HBSS. Following washing, medium was changed to
Iscove's DMEM (supplemented with 10% autologous
serum) containing either gliotoxin (0.1 μg/ml), B8 or B16
(20 μM) or no drug (DMSO 0.1% control). Cells were left
to incubate (37°C) for 30 min. Drug concentration and
incubation times were chosen from pilot studies that
demonstrated them to give optimum results in this sys-
tem. LPS (10 ng/ml) or vehicle (Iscove's DMEM supple-
mented with 10% autologous serum) was then added on
top of the coverslip and left to incubate for a further 45
min. The cell-covered coverslips were then washed 3 times
with PBS and 1 ml of 3% paraformaldehyde (in deionised
water; dH2O) was added and the cells left to fix (RT) for
20 min. Coverslips were then washed a further 3 times
with PBS and subsequently incubated for 10 min at RT
with 1 ml of 50 mM glycine to quench any aldehyde
groups. Following another 3 PBS washes, 1 ml of blocking
solution (10% sheep serum in 0.2% fish skin gelatin
(Sigma) was added to the coverslips and they were left
overnight at 4°C. The following morning, after washing
the cells, 100 μl of primary antibody (NF-κB p65 mouse
anti-human, BD Biosciences cat no. 610868 [46]; 1:50
dilution in blocking solution) was added to the cells. 1 h
later, following three PBS washes, 100 μl of a 1:250 dilu-
tion (in blocking solution) of secondary antibody (Alexa
Fluor® 488 goat anti-mouse IgG, Invitrogen cat no. A-
11001) was added and left to incubate for 1 h at RT in the
dark. Finally, three PBS washes, followed by three dH2O
washes were carried out to prevent crystal formation. Cov-
erslips were then mounted onto slides using Moviol (Cal-
biochem, Merck, Nottingham, UK) and the slides were
then stored in the dark at 4°C. Images from the immun-
ofluorescence slides were captured with a camera con-
nected to a Zeiss Axiovert S100 microscope using
Improvision Openlab 3.1.5 software. Images were cap-
tured at a magnification of ×100.
Statistical analyses
Statistical analysis was by 1-way analysis of variance
(ANOVA) with Dunnett's post-test where applicable and
was performed using GraphPad Prism version 4 (Graph-
Pad Software, San Diego, USA). ** is used to represent a P
value < 0.01, * denotes a P value < 0.05 and P values
greater than 0.05 were deemed not significant. Where
expressed, data are in the form mean ± standard error of
the mean (S.E.M.).
Results
Effect on NO-furoxans on TNFα Release
B8 had a significant inhibitory effect on TNFα release in
human monocyte-derived macrophages treated with LPS
(36 ± 10% of LPS control, P <0.01; n = 5–10 separate
donors, Fig. 2). The effect was equivalent in magnitude to
that of dexamethasone, but was not shared by DEA/NO,
B7, the furazans, aspirin or NCX4016. In monocytes, B8,
and to a lesser extent, its NO-free equivalent, B16, signifi-
cantly inhibited TNFα release [to 28 ± 5% (P < 0.01), and
49 ± 9% (P < 0.05) of control respectively, n = 4–6). Basal
TNFα levels were 0.9 ± 0.2 pg/ml for macrophages and 1.6
± 0.4 pg/ml for monocytes. After LPS-treatment these rose
to 5.5 ± 0.5 and 9.6 ± 0.3 ng/ml respectively.
Effect on NO-furoxans on LDH Release
None of the treatments studied caused significant cell
death (Fig. 3) compared with untreated macrophages and
monocytes. Levels of LDH released following the treat-
ments were comparable with that from untreated control
samples (~0.5 × 105 cells/treatment).
Effect on NO-furoxans on NF-κB activation
In order to investigate the potential molecular mechanism
of action of the inhibitory effect of B8 on macrophage
TNF-α release we investigated the effect of the compound
on LPS-stimulated NF-κB activation. For this we assessed
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the effect of B8 on the loss of the cytoplasmic inhibitory
subunit of NF-κB, IκBα (Fig. 4a and 4b shows two typical
western blots of cytoplasmic IκBα). In both blots LPS
causes a dramatic loss of cytoplasmic IκBα, an effect that
was completely inhibited by the NF-κB inhibitor glio-
toxin. Similarly, B8 at 100 μM also blocked LPS-induced
loss of cytoplasmic IκBα (Fig. 4a and 4b) whereas 1 and
10 μM B8 (Fig. 4b) did not affect LPS loss of IκB. The con-
centration of B8 that appears to be on the threshold of
inhibition appears to be around 20 μM (Fig. 4a). In order
to confirm that B8 inhibits NF-κB activation more
directly, we used immunofluorescence to investigate its
effect on LPS stimulation of NF-κB p65 subunit transloca-
tion from the cytoplasm to the nucleus. NF-κB p65
immunofluorescence revealed that the subunit location
varied according to the drug treatment. Control cells dis-
played uniform staining throughout the cytoplasm, but
following stimulus with LPS, strong staining was observed
in the nucleus and much less in the cytoplasm (Fig. 5a, b).
Incubation with gliotoxin before the LPS stimulus inhib-
ited the nuclear translocation of p65 as demonstrated by
the presence of cytoplasmic staining (Fig. 5c). Pre-incuba-
tion with the NO-aspirin B8 gave a dramatic shift in the
staining compared to the LPS control. Location of the NF-
κB p65 subunit was now revealed to be cytoplasmic (Fig.
5d). Cells treated with the NO-free equivalent of B8, B16,
Effect of potential anti-inflammatory agents on LPS (10 ng/ml)-induced TNFα release in human (a) monocyte-derived acrophages and (b) monocytes after 4 h treatm nt with 10 μM of either DEA/NO, B8, B16, B7, B15, NCX4016 or aspi-rin or 1 μM of dexam thasone (Dex)Figu e 2
Effect of potential anti-inflammatory agents on LPS 
(10 ng/ml)-induced TNFα release in human (a) 
monocyte-derived macrophages and (b) monocytes 
after 4 h treatment with 10 μM of either DEA/NO, 
B8, B16, B7, B15, NCX4016 or aspirin or 1 μM of dex-
amethasone (Dex). For macrophages n = 5–10 and for 
monocytes n = 4–6 separate donors. ** = p < 0.01 * = p < 
0.05 determined by One-Way ANOVA followed by Dun-
nett's test.
a 
b 
Bar graphs show LDH measurement in (a) monocyte-derived macrophages and (b) monocyt  super atants after reatmentwith 10 μM of either DEA/NO, B8, B16, B7, B15, NCX4016or aspirin or 1 μM of dex methasone (Dex) a d s imulat d LPS (10 ng/ml)Figu e 3
Bar graphs show LDH measurement in (a) mono-
cyte-derived macrophages and (b) monocyte super-
natants after treatment with 10 μM of either DEA/
NO, B8, B16, B7, B15, NCX4016 or aspirin or 1 μM of 
dexamethasone (Dex) and stimulated with LPS (10 
ng/ml). For macrophages n = 5–15 and for monocytes n = 6 
separate donors. One-way ANOVA revealed that there 
were no significant differences between groups in either cell 
type.
a 
b 
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displayed cytoplasmic staining but with a greater amount
of nuclear staining than B8 treated cells (Fig. 5e).
Discussion
Impact of NO-furoxans on TNFα-Release by Macrophages 
and Monocytes
The NO-aspirin, B8, had a significant inhibitory effect on
TNF-α release from human monocyte-derived macro-
phages treated with LPS. In monocytes B8, and to a lesser
extent, its NO-free equivalent, B16 again caused signifi-
cant inhibition of TNF-α release. In monocyte-derived
macrophages, the lack of effects of B16 and aspirin suggest
that the inhibitory effect of B8 on TNFα release is NO-
mediated. However, as this effect is not mimicked by the
NO-donor, DEA/NO, it is apparently a specific property of
B8 that is possibly related to amount, duration or site of
NO release. The possibility of diminished release of TNFα
by B8-treated cells being simply due to a cytotoxic effect of
the compound was not supported by results from the
LDH assay. None of the treatments significantly affected
cell death when compared with untreated cells.
In monocytes, TNFα release was inhibited by the NO-
aspirin, B8, but also by its NO-free furazan counterpart,
B16. Aspirin showed no significant difference from the
LPS control. Similar to the macrophage results, DEA/NO
did not cause significant inhibition. Again, B8 could be
acting via an NO-mediated mechanism specific to the
amount, duration or site of NO release. However, the
interesting observation that NO-free, B16 also causes a
significant inhibition suggests a possible further mecha-
nism. As previously demonstrated, the acetyl group of
Western blots showing the effects of varying concentrations of B8 o  IκBαFigure 4
Western blots showing the effects of varying concen-
trations of B8 on IκBα. Mononuclear cells were prepared 
as per methods, plated on 6-well plates, allowed to adhere 
for 1 h then treated with varying concentrations of B8 (1 μM, 
10 μM, 20 μM, 100 μM), gliotoxin (0.1 μg/ml), buffer or a 
DMSO vehicle control (0.2%) for 30 min at 37°C. After this 
interval LPS (10 ng/ml) or buffer was added to appropriate 
wells and left to incubate for a further 45 min. Lysates were 
prepared, total protein determined and 24 μg of protein per 
well was run on a 12% SDS-PAGE gel, transferred to PVDF. 
Blots were blocked before probing with rabbit IκB-α diluted 
1:2500, incubated overnight at 4°C. Subsequently, the blots 
were washed and incubated with goat anti-rabbit HRP, also 
diluted 1:2500, then developed using standard ECL. Blots are 
representative of at least 6 similar experiments.
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Representative immunofluorescence imagesFigure 5
Representative immunofluorescence images. Image a 
shows a control treated monocyte. Image b shows a mono-
cyte following a 45 min LPS stimulus. Image c shows a mono-
cyte treated with gliotoxin (0.1 μg/ml, 30 min) and stimulated 
with LPS (10 ng/ml, 45 min). Image d shows a monocyte 
treated with B8 (20 μM, 30 min) and stimulated with LPS (10 
ng/ml, 45 min). Image e shows a monocyte treated with B16 
(20 μM, 30 min) and stimulated with LPS (10 ng/ml, 45 min). 
C = cytoplasm. N = nucleus. Scale bar represents 100 μm. 
Similar images were obtained on at least 3 separate experi-
ments.
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these compounds is lost in plasma [12], leaving salicylic
acid, through which, inhibition of cytokine release has
been reported [47-49]. It may therefore be possible that
under these experimental conditions, a salicylic acid-
mediated mechanism is responsible for the inhibition of
TNFα release observed with B8- and B16-treated cells. It is
probable that the result obtained with B8 is achieved
through combination of the effects of NO (as illustrated
by DEA/NO) and that of the NO-free B16. We have previ-
ously shown that the furoxan-aspirin B7 releases signifi-
cantly less NO than B8 [19] and thus suggest that the NO
release from B7 is insufficient to result in an anti-inflam-
matory effect similar to that of B8. Our result obtained
with B16 indicates that altering the chemical structure of
aspirin clearly has an impact on the ability to achieve anti-
inflammatory properties in this assay. Furthermore, the
alteration to the aspirin structure in B15 and B7 likely
contributed to their poor performance in this assay.
In this study, aspirin did not significantly reduce TNFα
release from LPS-stimulated monocytes or macrophages.
This is consistent with a similar study in which aspirin
failed to have an effect even at a 30-fold higher concentra-
tions than was used in the present study [50]. A further
study did report an inhibitory effect of aspirin on TNFα
release from LPS-stimulated monocytes but this was at
concentrations of 5–10 mM [49], which may not be rep-
resentative of pharmacologically relevant plasma concen-
trations [51]. We show here that NCX4016 did not
significantly reduce the release of TNFα. In a study carried
out by others, NCX4016 did not inhibit TNFα release at
the same concentration used here (10 μM), but was
shown to inhibit the release of TNFα and IL-6 from LPS-
stimulated macrophages at higher (100 and 300 μM) con-
centrations and following a 6 h incubation [50]. Despite
not being affected by the soluble guanylate cyclase inhib-
itor ODQ, the authors suggest that the inhibitory effect of
NCX4016 is NO-mediated due to the failure of aspirin to
inhibit cytokine release. A further study also showed that
NCX4016 (again at concentrations 10-fold higher than
used in this study), inhibited the release of IL-1β and IL-
18 from LPS-stimulated monocytes, via NO-mediated
inhibition of the enzyme required for intracellular
processing and maturation of IL-1 and IL-18 (caspase-1)
activity [52]. It is likely that the differing outcomes
observed between this and other studies are purely due to
drug incubation time or concentrations. The concentra-
tion studied here is based on the realistic relevant plasma
concentrations of aspirin [51] and so is more demonstra-
tive of the true therapeutic potential of the drug. The
results here show that at a concentration at which the
furoxan compound, B8, causes a significant 72% reduc-
tion in TNFα release from monocytes and a 64% reduc-
tion from macrophages, its organic nitrate counterpart
does not.
Possible explanations for the differential effects of the
same treatments observed between monocytes and mac-
rophages effect may be the differential expression and
activity of receptors and signalling pathways between the
two cell types. It has previously been reported that the
anti-inflammatory effect of IL-4 on the release of TNFα
and other cytokines, varies between LPS-stimulated
monocytes and macrophages [53]. This effect is due to
loss of a receptor for IL-4 during monocyte differentiation
[53]. Other differences reported between monocytes and
macrophages include those showing that LPS activates
cytosolic PLA2 in monocytes but not in macrophages. A
similar activation in monocytes, but not macrophages, is
seen after LPS-stimulation in the following signalling
pathways: the MAP kinase, ERK, phosphatidylinositol-3
kinase and p70S6 kinase [54,55]. Further variations
include increased expression of Ca2+-dependent protein
kinase C isoforms in monocytes when compared to mac-
rophages [56] and also that maturation into macrophages
results in slower production of the cytokine, IL-1β [57]. It
is, therefore, possible that changes such as these to recep-
tor expression, signalling pathways and to the biosynthe-
sis of cytokines, which normally occur during the
maturation of monocytes with macrophages, may impact
on the ability of the studied compounds to have a signifi-
cant effect.
Impact of NO-furoxans on NF-κB Activation in Monocytes
The western blot and immunofluorescence experiments
further suggested a possible mechanism for the B8-medi-
ated inhibition of TNFα release. The transcription factor,
NF-κB, exists as a dimer (can be either a homodimer or
heterodimer). The most common form is a heterodimer
composed of the p65/p50 subunits [58]. Normally, NF-κB
is kept in an inactive state in the cytoplasm, bound to an
inhibitory subunit named IκBα [59]. The phosphoryla-
tion of IκBα by a kinase known as IKK and the subsequent
degradation of IκBα leads to the activation of the NF-κB
[60]. The NF-κB dimer containing the p65 subunit; the
dominant factor in the induction of the TNFα gene, then
translocates from the cytoplasm to the nucleus where it
activates transcription of target genes such as TNFα
[25,27,61,62]. To investigate the effect of the NO-aspirin
on stimulus (LPS)-induced NF-κB activation, we used two
independent assays; namely loss of cytoplasmic IκBα
assessed by western blotting and translocation of the p65
subunit of NF-κB assessed by immunofluorescence. For
consistency, LPS was used as our NF-κB-activating stimu-
lus and epipolythiodioxoperazine (gliotoxin), a known
immunosuppressive agent that inhibits NF-κB activation
by preventing IκBα degradation [43,63], was used as the
positive control. LPS caused a dramatic loss of cytoplas-
mic IκBα and translocation of cytoplasmic p65 to the
nucleus, effects that were inhibited by NO-aspirin B8 and
the positive control gliotoxin. Thus, the inhibition of NF-
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κB activation provides a plausible explanation for the B8-
induced reduction in TNFα release as observed in the
ELISA studies. It has been shown that NO inhibits LPS-
induced IκB-phosphorylation and inhibits the activation
of NF-κB [35], further supporting our paradigm of NO-
mediated inhibition of TNFα release by B8. B16-treated
and LPS-stimulated monocytes also displayed some evi-
dence of cytoplasmic staining, but with more nuclear
staining than its NO counterpart. This result is consistent
with the ELISA data, where significant inhibition of TNFα
release, albeit lesser than B8-treated cells, was observed
following B16 treatment.
Therapeutic Implications
The data here show that the furoxan-aspirin compound
B8 has anti-inflammatory effects in LPS-stimulated
monocytes and macrophages through its reduction in NF-
κB-mediated TNFα release. This action of B8 may be use-
ful in inflammatory diseases (arthritis, Crohn's disease
and asthma [64-67] where anti-TNFα therapy is, or has
potential, to be of therapeutic benefit. Rheumatoid arthri-
tis is a chronic inflammatory autoimmune disorder char-
acterised by inflammation of the lining (synovium) of
joints. Joint deterioration, together with the pain associ-
ated with synovial inflammation can lead to substantial
loss of mobility. Pro-inflammatory cytokines are abun-
dant in the joints of sufferers [65]. Anti-TNFα drugs have
been recently licensed for use in arthritis in a bid to limit
the contribution of this cytokine to the chronic joint
inflammation [67]. Treatment of arthritis with drugs of
the NSAID class is severely limited due to the gastric side-
effects associated with the high doses and chronic nature
of the treatment required. However it is hoped that NO-
aspirins might offer a preferable alternative to therapy
with conventional NSAIDs. The multifaceted actions of
B8 on COX inhibition [19] the anti-TNFα effects demon-
strated here, its observed resistance to gastrotoxic effects
[12] and its potential for targeted intracellular release of
NO [19,68] could indicate B8 to be a promising anti-
arthritic drug. A summary of the effects of the furoxan-
aspirin hybrid drugs is provided in Fig. 6. A further, more
speculative application for drugs such as B8 is in athero-
sclerosis therapy. It is now widely accepted that inflamma-
tion is a key element in atherogenesis and atherosclerotic
plaque rupture leading to acute cardiovascular events such
as myocardial infarction or stroke [69]. The release of
TNFα by monocytes and macrophages causes various
effects involved in destabilising the atherosclerotic plaque
[70-74]. Such evidence may suggest that drugs with an
anti-TNFα action, such as B8, may be of benefit in athero-
sclerosis.
Conclusion
Taken together, these studies provide evidence that treat-
ment with NO-aspirin B8, significantly reduced TNFα
release from both LPS-stimulated monocytes and mono-
cyte-derived macrophages. A possible mechanism for this
anti-inflammatory action is through the inhibition of its
transcription factor, NF-κB by NO. Such an action instils
a potential for drugs of this NO-aspirin hybrid class to be
utilised as anti-inflammatory agents for the treatment of a
wide range of inflammatory conditions such as arthritis.
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